|
US6277975B1
(en)
|
1992-10-23 |
2001-08-21 |
Genetics Institute, Inc. |
Fusions of P-selectin ligand protein and polynucleotides encoding same
|
|
US20030143662A1
(en)
|
1998-06-16 |
2003-07-31 |
Cummings Richard D. |
Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
|
|
AU773542B2
(en)
|
1998-06-16 |
2004-05-27 |
Board Of Regents Of The University Of Oklahoma, The |
Glycosulfopeptides and methods of synthesis and use thereof
|
|
US7223845B2
(en)
|
1998-06-16 |
2007-05-29 |
The Board Of Regents Of The University Of Oklahoma |
Synthetic glycosulfopeptides and methods of synthesis thereof
|
|
EP1131084A4
(en)
*
|
1998-10-30 |
2001-12-19 |
Genetics Inst |
INHIBITION OF DIFFERENTIATION OF CYTOTOXIC T CELLS BY P-SELECTINE LIGAND ANTAGONISTS (PSGL)
|
|
CA2347940A1
(en)
*
|
1998-11-21 |
2000-06-02 |
The Regents Of The University Of California |
Use of core 2 glcnac transferase inhibitors in treating inflammation
|
|
US6492152B1
(en)
|
1999-06-15 |
2002-12-10 |
The Board Of Regents Of The University Of Oklahoma |
Core 1 β3-galactosyl transferases and methods of use thereof
|
|
US7256171B1
(en)
|
1999-11-20 |
2007-08-14 |
The Regents Of The University Of California |
Use of core 2 G1cNAc transferase inhibitors in treating inflammation
|
|
EP1325123A4
(en)
*
|
2000-09-12 |
2004-07-21 |
Inst Genetics Llc |
STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS
|
|
EP1406930A4
(en)
*
|
2000-12-29 |
2007-01-10 |
Savient Pharmaceuticals Inc |
"ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF"
|
|
US20040116333A1
(en)
|
2001-08-03 |
2004-06-17 |
Rong-Hwa Lin |
Modulators of P-selectin glycoprotein ligand 1
|
|
US7744888B2
(en)
|
2001-08-03 |
2010-06-29 |
Abgenomics Cooperatief U.A. |
Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
|
|
AU2003255337A1
(en)
*
|
2002-07-31 |
2004-02-23 |
Kylix B.V. |
Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
|
|
JP4599027B2
(ja)
*
|
2002-10-30 |
2010-12-15 |
東洋水産株式会社 |
Ｌ−セレクチン結合阻害剤
|
|
FI20021989A0
(fi)
*
|
2002-11-06 |
2002-11-06 |
Halina Miller-Podraza |
Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
|
|
GB0513881D0
(en)
|
2005-07-06 |
2005-08-10 |
Btg Int Ltd |
Core 2 GLCNAC-T Inhibitors III
|
|
GB0329667D0
(en)
|
2003-12-22 |
2004-01-28 |
King S College London |
Core 2 GlcNAc-T inhibitor
|
|
US20080182801A1
(en)
|
2003-12-22 |
2008-07-31 |
Btg International Limited |
Core 2 glcnac-t inhibitors
|
|
UY28886A1
(es)
|
2004-05-10 |
2005-12-30 |
Boehringer Ingelheim Int |
Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
|
|
MXPA06012987A
(es)
|
2004-05-11 |
2007-06-12 |
Abgenomics Corp |
Epitopos inductores de muerte de celulas t.
|
|
GB0513888D0
(en)
|
2005-07-06 |
2005-08-10 |
Btg Int Ltd |
Core 2 GLCNAC-T Inhibitors II
|
|
GB0513883D0
(en)
|
2005-07-06 |
2005-08-10 |
Btg Int Ltd |
Diagnosis of Atherosclerosis
|
|
US20070298034A9
(en)
*
|
2005-12-09 |
2007-12-27 |
Angela Widom |
Sulfotyrosine specific antibodies and uses therefor
|
|
JP5331293B2
(ja)
*
|
2006-04-28 |
2013-10-30 |
公益財団法人野口研究所 |
多様性を表現するオリゴ糖またはその誘導体
|
|
PT2321235T
(pt)
*
|
2008-09-02 |
2019-06-25 |
Construction Research & Technology Gmbh |
Utilização de uma composição aceleradora de endurecimento que contém plastificante
|
|
BR112012009500A2
(pt)
*
|
2009-10-21 |
2016-11-29 |
Eth Zuerich |
utilidade médica de proteínas de ligação de glicano e glicanos
|
|
US20130209449A9
(en)
|
2011-06-13 |
2013-08-15 |
Abgenomics Cooperatief U.A. |
Anti-psgl-1 antibodies and uses thereof
|
|
KR102630011B1
(ko)
|
2017-01-11 |
2024-01-26 |
브리스톨-마이어스 스큅 컴퍼니 |
Psgl-1 길항제 및 그의 용도
|
|
EP3595720A4
(en)
|
2017-03-14 |
2021-05-26 |
Five Prime Therapeutics, Inc. |
ANTIBODIES BINDING VISTA AT ACIDIC PH VALUE
|
|
MX2020009786A
(es)
|
2018-03-21 |
2020-10-12 |
Five Prime Therapeutics Inc |
Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido.
|
|
WO2020014327A2
(en)
|
2018-07-11 |
2020-01-16 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic ph
|